Community Health Systems (CYH) 10-Q 28 Jul 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Jul. 21, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity File Number	001-15925
Entity Registrant Name	COMMUNITY HEALTH SYSTEMS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3893191
Entity Address, Address Line One	4000 Meridian Boulevard
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	465-7000
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	CYH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		134,713,069
Entity Central Index Key	0001108109
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of (Loss) Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net operating revenues	$ 2,934	$ 3,007	$ 6,044	$ 6,020
Operating costs and expenses:
Salaries and benefits	1,295	1,266	2,620	2,569
Supplies	487	500	985	992
Other operating expenses	830	715	1,683	1,453
Lease cost and rent	78	78	155	156
Pandemic relief funds	(8)	(1)	(55)	(83)
Depreciation and amortization	133	133	261	272
Impairment and (gain) loss on sale of businesses, net		2	6	23
Total operating costs and expenses	2,815	2,693	5,655	5,382
Income from operations	119	314	389	638
Interest expense, net	218	219	435	449
Loss from early extinguishment of debt		8	5	79
Equity in earnings of unconsolidated affiliates	(1)	(4)	(6)	(15)
(Loss) income before income taxes	(98)	91	(45)	125
Provision for income taxes	200	54	223	123
Net (loss) income	(298)	37	(268)	2
Less: Net income attributable to noncontrolling interests	28	31	59	60
Net (loss) income attributable to Community Health Systems, Inc. stockholders	$ (326)	$ 6	$ (327)	$ (58)
(Loss) earnings per share attributable to Community Health Systems, Inc. stockholders:
Basic	$ (2.52)	$ 0.04	$ (2.54)	$ (0.46)
Diluted	$ (2.52)	$ 0.04	$ (2.54)	$ (0.46)
Weighted-average number of shares outstanding:
Basic	129,095,571	127,069,252	128,460,419	126,414,901
Diluted	129,095,571	130,737,124	128,460,419	126,414,901

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (298)	$ 37	$ (268)	$ 2
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of available-for-sale debt securities, net of tax	(6)	1	(14)	(3)
Amortization and recognition of unrecognized pension cost components, net of tax				1
Other comprehensive (loss) income	(6)	1	(14)	(2)
Comprehensive (loss) income	(304)	38	(282)
Less: Comprehensive income attributable to noncontrolling interests	28	31	59	60
Comprehensive (loss) income attributable to Community Health Systems, Inc. stockholders	$ (332)	$ 7	$ (341)	$ (60)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 346	$ 507
Patient accounts receivable	2,001	2,062
Supplies	356	355
Prepaid income taxes	99	94
Prepaid expenses and taxes	263	192
Other current assets	264	269
Total current assets	3,329	3,479
Property and equipment	9,759	9,757
Less accumulated depreciation and amortization	(4,220)	(4,204)
Property and equipment, net	5,539	5,553
Goodwill	4,224	4,219
Deferred income taxes	53	53
Other assets, net	1,913	1,913
Total assets	15,058	15,217
Current liabilities:
Current maturities of long-term debt	32	31
Current operating lease liabilities	153	147
Accounts payable	832	830
Accrued liabilities:
Employee compensation	624	655
Accrued interest	221	225
Other	433	476
Total current liabilities	2,295	2,364
Long-term debt	12,183	12,109
Deferred income taxes	410	192
Long-term operating lease liabilities	569	535
Other long-term liabilities	759	827
Total liabilities	16,216	16,027
Redeemable noncontrolling interests in equity of consolidated subsidiaries	498	480
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued
Common stock, $.01 par value per share, 300,000,000 shares authorized; 134,683,113 shares issued and outstanding at June 30, 2022, and 132,146,282 shares issued and outstanding at December 31, 2021	1	1
Additional paid-in capital	2,090	2,118
Accumulated other comprehensive loss	(27)	(14)
Accumulated deficit	(3,804)	(3,477)
Total Community Health Systems, Inc. stockholders’ deficit	(1,740)	(1,372)
Noncontrolling interests in equity of consolidated subsidiaries	84	82
Total stockholders’ deficit	(1,656)	(1,290)
Total liabilities and stockholders’ deficit	$ 15,058	$ 15,217

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	134,683,113	132,146,282
Common stock, shares outstanding	134,683,113	132,146,282

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net (loss) income	$ 37	$ (268)	$ 2
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	133	261	272
Deferred income taxes		221	118
Stock-based compensation expense	5	8	13
Impairment and (gain) loss on sale of businesses, net	2	6	23
Loss from early extinguishment of debt	8	5	79
Other non-cash expenses, net		95	(3)
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable		61	(32)
Supplies, prepaid expenses and other current assets		(72)	31
Repayment/derecognition of Medicare accelerated payments			(134)
Accounts payable, accrued liabilities and income taxes		(63)	(2)
Other		(100)	(87)
Net cash provided by operating activities		154	280
Cash flows from investing activities:
Acquisitions of facilities and other related businesses		(4)	(4)
Purchases of property and equipment		(191)	(212)
Proceeds from disposition of hospitals and other ancillary operations		3	7
Proceeds from sale of property and equipment		7	3
Purchases of available-for-sale debt securities and equity securities		(55)	(63)
Proceeds from sales of available-for-sale debt securities and equity securities		41	48
Purchases of investments in unconsolidated affiliates		(8)	(2)
Increase in other investments		(30)	(32)
Net cash used in investing activities		(237)	(255)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements		(8)	(5)
Deferred financing costs and other debt-related costs		(73)	(310)
Proceeds from noncontrolling investors in joint ventures		1
Redemption of noncontrolling investments in joint ventures		(1)	(3)
Distributions to noncontrolling investors in joint ventures		(73)	(66)
Other borrowings		34	19
Issuance of long-term debt		1,535	4,310
Repayments of long-term indebtedness		(1,493)	(4,396)
Net cash used in financing activities		(78)	(451)
Net change in cash and cash equivalents		(161)	(426)
Cash and cash equivalents at beginning of period		507	1,676
Cash and cash equivalents at end of period	1,250	346	1,250
Supplemental disclosure of cash flow information:
Interest payments	(101)	(410)	(304)
Income tax payments, net	$ (1)	$ (6)	$ (1)

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of June 30, 2022 and December 31, 2021 and for the three-month and six-month periods ended June 30, 2022 and 2021, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2022. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions. Certain information and disclosures normally included in the notes to the consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 17, 2022 (“2021 Form 10-K”). Reclassifications . Certain prior period amounts have been reclassified to conform to the current period presentation within the condensed consolidated statements of cash flows. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets. Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company include the Company’s corporate office costs at its Franklin, Tennessee office, which were $57 million and $52 million for the three months ended June 30, 2022 and 2021, respectively, and $120 million and $112 million for the six months ended June 30, 2022 and 2021, respectively. Throughout these notes to the unaudited condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of Community Health Systems, Inc. Revenue Recognition. Net Operating Revenues Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions. During each of the three and six-month periods ended June 30, 2022 and 2021, the impact of changes to the inputs used to determine the transaction price was considered immaterial. Currently, several states utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (“CMS”) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and payment is reasonably assured. Reimbursement under these programs is reflected in net operating revenues. Taxes or other program-related costs are reflected in other operating expenses. The Company’s net operating revenues during the three and six months ended June 30, 2022 and 2021 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Medicare $ 616 $ 642 $ 1,285 $ 1,335 Medicaid 445 420 912 811 Managed Care and other third-party payors 1,862 1,919 3,794 3,835 Self-pay 11 26 53 39 Total $ 2,934 $ 3,007 $ 6,044 $ 6,020 Patient Accounts Receivable Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends. Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, the impact of recent acquisitions and dispositions and the impact of current economic and other events. Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $107 million and $118 million as of June 30, 2022 and December 31, 2021, respectively, and these amounts are included in accrued liabilities-other in the accompanying condensed consolidated balance sheets. Amounts due from third-party payors were $100 million and $114 million as of June 30, 2022 and December 31, 2021, respectively, and are included in other current assets in the accompanying condensed consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2017. Charity Care In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government. The Company updated its policy during the three months ended March 31, 2022 in a manner which increased the number of accounts qualifying for charity care. This resulted in an increase in charity care services during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021. These charity care services are estimated to be $ 409 Accounting for the Impairment or Disposal of Long-Lived Assets. During the six months ended June 30, 2022, the Company recorded an impairment charge of approximately $6 million to adjust the carrying value of long-lived assets at a hospital that was subsequently sold at a sales price below carrying value. During the six months ended June 30, 2021, the Company recorded a total combined net loss on disposal of approximately $23 million, of which (i) The Company will continue to evaluate the potential for impairment of the long-lived assets of hospitals and other held-and-used businesses as well as evaluate offers for potential sales, as applicable. Based on such analysis, additional impairment charges may be recorded in the future. Pandemic Relief Funds During the six months ended June 30, 2022 and 2021, the Company received approximately $52 million and $7 million, respectively, in pandemic relief fund payments through various federal, state and local programs. Approximately $8 million and $1 million during the three months ended June 30, 2022 and 2021, respectively, and $55 million and $83 million during the six months ended June 30, 2022 and 2021, respectively, was recognized as a reduction to operating costs and expenses, as denoted by the caption “pandemic relief funds” within the condensed consolidated statements of (loss) income. Approximately $11 million of unrecognized pandemic relief funds received are reflected within accrued liabilities-other in the condensed consolidated balance sheet as of June 30, 2022. Such unrecognized amounts may either be returned or may be recognized in future periods if the underlying conditions for recognition are reasonably assured of having been met. The Company’s accounting policies for the recognition of pandemic relief funds is unchanged from the policies described in Note 1 to the Company’s consolidated financial statements included in the 2021 Form 10-K.

Accounting for Stock-Based Comp

Accounting for Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
ACCOUNTING FOR STOCK-BASED COMPENSATION	2. ACCOUNTING FOR STOCK-BASED COMPENSATION Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2009 Stock Option and Award Plan, which was amended and restated as of March 17, 2021 and approved by the Company’s stockholders at the annual meeting of stockholders held on May 11, 2021 The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (“IRC”) and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. As of June 30, 2022, 6,906,176 shares of unissued common stock were reserved for future grants under the 2009 Plan. The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Effect on (loss) income before income taxes $ (3 ) $ (5 ) $ (8 ) $ (13 ) Effect on net (loss) income $ (2 ) $ (4 ) $ (7 ) $ (10 ) At June 30, 2022, $45 million of unrecognized stock-based compensation expense related to outstanding unvested stock options, restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 27 months. Of that amount, $7 million relates to outstanding unvested stock options expected to be recognized over a weighted-average period of 26 months and $38 million relates to outstanding unvested restricted stock and restricted stock units expected to be recognized over a weighted-average period of 27 months. There were no modifications to awards during the six months ended June 30, 2022 and 2021. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, these options vest in one-third increments on each of the first three anniversaries of the award date and have a 10-year contractual term. The exercise price of all options granted under the 2009 Plan is equal to the fair value of the Company’s common stock on the option grant date. The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Expected volatility N/A N/A 84.3% - 87.5% 84.3% - 88.9% Expected dividends N/A N/A — — Expected term N/A N/A 3 - 6 years 3 - 6 years Risk-free interest rate N/A N/A 1.5% - 1.6% 0.3% - 0.9% In determining the expected term, the Company examined concentrations of option holdings and historical patterns of option exercises and forfeitures, as well as forward-looking factors, in an effort to determine if there were any discernable employee populations. From this analysis, the Company identified two primary employee populations, one consisting of certain senior executives and the other consisting of substantially all other recipients. The expected volatility rate was estimated based on historical volatility. In determining expected volatility, the Company also reviewed the market-based implied volatility of actively traded options of its common stock and determined that historical volatility utilized to estimate the expected volatility rate did not differ significantly from the implied volatility. The expected term computation is based on historical exercise and cancellation patterns and forward-looking factors, where present, for each population identified. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company adjusts the estimated forfeiture rate to its actual experience. Options outstanding and exercisable under the 2009 Plan as of June 30, 2022, and changes during each of the three-month periods following December 31, 2021, was as follows (in millions, except share and per share data): Weighted- Aggregate Weighted- Average Intrinsic Average Remaining Value as of Exercise Contractual June 30, Shares Price Term 2022 Outstanding at December 31, 2021 2,301,753 $ 6.77 Granted 760,000 10.18 Exercised (56,500 ) 4.97 Forfeited and cancelled (151,002 ) 14.67 Outstanding at March 31, 2022 2,854,251 7.30 Granted — — Exercised — — Forfeited and cancelled — — Outstanding at June 30, 2022 2,854,251 $ 7.30 8.3 years $ — Exercisable at June 30, 2022 1,320,912 $ 5.63 7.5 years $ — The weighted-average grant date fair value of stock options granted during the six months ended June 30, 2022 and 2021 was $7.25 and $6.22, respectively. The aggregate intrinsic value (calculated as the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($3.75) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on June 30, 2022. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised was less than $1 million during both of the six-month periods ended June 30, 2022 and 2021. No options were exercised during the three-month periods ended June 30, 2022 and 2021. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options. The Company has also awarded restricted stock under the 2009 Plan to employees of certain subsidiaries. With respect to time-based vesting restricted stock that has been awarded under the 2009 Plan, the restrictions on these shares have generally lapsed in one-third increments on each of the first three anniversaries of the award date. In addition, certain of the restricted stock awards granted to the Company’s senior executives have contained performance objectives required to be met in addition to any time-based vesting requirements. If the applicable performance objectives are not attained, these awards will be forfeited in their entirety. For performance-based awards, the performance objectives are measured cumulatively over a three-year Restricted stock outstanding under the 2009 Plan as of June 30, 2022, and changes during each of the three-month periods following December 31, 2021, was as follows: Weighted- Average Grant Shares Date Fair Value Unvested at December 31, 2021 4,995,314 $ 6.30 Granted 3,179,000 9.05 Vested (2,516,247 ) 5.62 Forfeited (30,000 ) 6.87 Unvested at March 31, 2022 5,628,067 8.61 Granted 41,000 5.00 Vested (17,000 ) 10.65 Forfeited (72,670 ) 9.77 Unvested at June 30, 2022 5,579,397 8.56 Restricted stock units (“RSUs”) have been granted to the Company’s non-management directors under the 2009 Plan. Each of the Company’s then serving non-management directors received grants under the 2009 Plan of 17,682 RSUs and 19,296 RSUs on March 1, 2022 and 2021, respectively. The March 2022 and 2021 grants had a grant date fair value of approximately $180,000 and $170,000, respectively. On June 1, 2022, a new non-management director received a grant of 17,682 RSUs with a grant date fair value of approximately $88,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date or upon the director’s earlier cessation of service on the board, other than for cause. Each non-management director may elect, prior to the beginning of the calendar year in which the award is granted, to defer the receipt of shares of the Company’s common stock issuable upon vesting until either his or her (i) separation from service with the Company or (ii) attainment of an age specified in advance by the non-management director. A total of three directors elected to defer the receipt of RSUs granted on March 1, 2022 to a future date and a total of four directors elected to defer the receipt of RSUs granted on March 1, 2021 to a future date. RSUs outstanding under the 2009 Plan as of June 30, 2022, and changes during each of the three-month periods following December 31, 2021, was as follows: Weighted- Average Grant Shares Date Fair Value Unvested at December 31, 2021 486,598 $ 6.17 Granted 159,138 10.18 Vested (151,058 ) 5.63 Forfeited — — Unvested at March 31, 2022 494,678 7.63 Granted 17,682 5.00 Vested — — Forfeited — — Unvested at June 30, 2022 512,360 7.54

Acquisitions and Divestitures

Acquisitions and Divestitures	6 Months Ended
	Jun. 30, 2022
Acquisitions And Divestitures [Abstract]
ACQUISITIONS AND DIVESTITURES	3. ACQUISITIONS AND DIVESTITURES Acquisitions The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control of the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired. During the six months ended June 30, 2022, one or more subsidiaries of the Company paid approximately $4 million to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. The Company allocated the purchase price to property and equipment, working capital, noncontrolling interests and goodwill. Divestitures No hospitals were divested during the six months ended June 30, 2022. The following table provides a summary of hospitals that the Company divested during the year ended December 31, 2021: Licensed Hospital Buyer City, State Beds Effective Date Lea Regional Medical Center Covenant Health System Hobbs, NM 84 January 1, 2021 Tennova Healthcare - Tullahoma Vanderbilt University Medical Center Tullahoma, TN 135 January 1, 2021 Tennova Healthcare - Shelbyville Vanderbilt University Medical Center Shelbyville, TN 60 January 1, 2021 Northwest Mississippi Medical Center Delta Health System Clarksdale, MS 181 February 1, 2021 AllianceHealth Midwest SSM Health Care of Oklahoma Midwest City, OK 255 April 1, 2021 On March 7, 2022, one or more affiliates of the Company entered into a definitive agreement for the sale of substantially all of the assets of AllianceHealth Seminole (32 licensed beds) in Seminole, Oklahoma, to affiliates of SSM Health Care of Oklahoma. This disposition was completed on July 1, 2022 as further described in Note 13. No divestitures or potential divestitures meet the criteria for reporting as a discontinued operation as of June 30, 2022.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	4. GOODWILL The changes in the carrying amount of goodwill for the six months ended June 30, 2022 are as follows (in millions): Balance, as of December 31, 2021 Goodwill $ 7,033 Accumulated impairment losses (2,814 ) 4,219 Goodwill acquired as part of acquisitions during current year 5 Goodwill allocated to hospitals held for sale — Balance, as of June 30, 2022 Goodwill 7,038 Accumulated impairment losses (2,814 ) $ 4,224 Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segment meets the criteria to be classified as a reporting unit. Goodwill is evaluated for impairment annually and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. The Company performed its last annual goodwill impairment evaluation during the fourth quarter of 2021 using an October 31, 2021 measurement date, which indicated no impairment. The Company estimates the fair value of the reporting unit using both a discounted cash flow model as well as a market multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions. The determination of fair value in the Company’s goodwill impairment analysis is based on an estimate of fair value for the reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of the Company’s common stock and fair value of long-term debt, recent financial results of the Company, estimates of future revenue and expense growth, estimated market multiples, expected capital expenditures, income tax rates, and costs of invested capital. A detailed evaluation of potential impairment indicators was performed as of June 30, 2022, which specifically considered declines in the fair market value of the Company’s outstanding senior secured and unsecured notes and common stock during the six months ended June 30, 2022, as well as macroeconomic conditions and the Company’s recent financial results, including the effect of increased wage and contract labor expense. On the basis of available evidence, as of June 30, 2022, the Company concluded that the fair value of the reporting unit was not more likely than not reduced to an amount less than its carrying value. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the assumptions described above changes materially in the future, including a decline in the Company’s stock price and the fair value of its long-term debt, an increase in the volatility of the Company’s stock price and the fair value of its long-term debt, lower than expected volumes and/or net operating revenues, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	5. INCOME TAXES The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was less than $1 million as of June 30, 2022. A total of less than $1 million of interest and penalties is included in the amount of the liability for uncertain tax positions at June 30, 2022. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its condensed consolidated statements of (loss) income as income tax expense. It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s condensed consolidated results of operations or financial position. The Company’s federal income tax return for the 2018 tax year remains under examination by the Internal Revenue Service. The Company believes the result of this examination will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2023 for the tax period ended December 31, 2018. The Company’s provision for income taxes was $200 million and $54 million for the three months ended June 30, 2022 and 2021, respectively, and $223 million and $123 million for the six months ended June 30, 2022 and 2021, respectively. The Company’s effective tax rates were (204.1)% and 59.3% for the three months ended June 30, 2022 and 2021, respectively, and (495.6)% and 98.4% for the six months ended June 30, 2022 and 2021, respectively. The increase in the provision for income taxes for the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 was primarily due to an increase in non-deductible interest as a result of a decline in projected adjusted taxable income for 2022 compared to 2021, compounded by an adverse change in the IRC Section 163(j) limit for deductible interest expense beginning in 2022. The difference in the Company’s effective tax rate for the three and six months ended June 30, 2022 compared to the three and six months June 30, 2021 is due to an increase in the provision for income taxes and the Company reporting loss before income taxes in the current year periods compared to income before income taxes in the prior year periods . Cash paid for income taxes, net of refunds received, resulted in a net payment of approximately $4 million and $1 million during the three months ended June 30, 2022 and 2021, respectively, and $6 million and $1 million during the six months ended June 30, 2022 and 2021, respectively.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2022
Long Term Debt And Capital Lease Obligations [Abstract]
LONG-TERM DEBT	6. LONG-TERM DEBT Long-term debt, net of unamortized deferred debt issuance costs, consists of the following (in millions): June 30, December 31, 2022 2021 6⅝ $ — $ 1,462 8% Senior Secured Notes due 2026 2,101 2,101 8% Senior Secured Notes due 2027 700 700 5⅝ 1,900 1,900 6⅞ 767 767 6% Senior Secured Notes due 2029 900 900 5¼ 1,535 — 4¾ 1,095 1,095 6⅞ 1,775 1,775 6⅛ 1,440 1,440 ABL Facility — — Finance lease and financing obligations 428 398 Other 48 37 Less: Unamortized deferred debt issuance costs and note premium (474 ) (435 ) Total debt 12,215 12,140 Less: Current maturities (32 ) (31 ) Total long-term debt $ 12,183 $ 12,109 On February 4, 2022, CHS/Community Health Systems, Inc. (“CHS”) completed a private offering of $1.535 billion aggregate principal amount of 5¼% Senior Secured Notes due May 15, 2030 (the “5¼% Senior Secured Notes due 2030”). The proceeds of the offering were used to redeem the 6⅝ The 5¼ 5¼ CHS is entitled, at its option, to redeem all or a portion of the 5¼ CHS may redeem up to 40% of the aggregate principal amount of the 5¼ At any time and from time to time on or after May 15, 2025, CHS may redeem the 5¼ Period Redemption Price May 15, 2025 to May 14, 2026 102.625% May 15, 2026 to May 14, 2027 101.313% May 15, 2027 to May 14, 2030 100.000% The maximum aggregate principal amount under the ABL Facility is $1.0 billion. At June 30, 2022, the available borrowing base under the ABL Facility was $978 million, of which $84 million was reserved for outstanding letters of credit and $894 million represented excess availability. Letters of credit were reduced during the six months ended June 30, 2022 by $19 million due to a reduction in an insurance-related letter of credit. The Company had no outstanding borrowings as of June 30, 2022. The issued letters of credit are primarily in support of potential insurance-related claims and certain bonds. The ABL Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) engage in mergers, acquisitions and asset sales, (7) conduct transactions with affiliates, (8) alter the nature of the Company’s, CHS’ or the guarantors’ businesses, (9) grant certain guarantees with respect to physician practices, (10) engage in sale and leaseback transactions or (11) change the Company’s fiscal year. The Company is also required to comply with a consolidated fixed charge coverage ratio, upon certain triggering events described below, and various affirmative covenants. The consolidated fixed charge coverage ratio is calculated as the ratio of (x) consolidated EBITDA (as defined in the ABL Facility) less capital expenditures to (y) the sum of consolidated interest expense (as defined in the ABL Facility), scheduled principal payments, income taxes and restricted payments made in cash or in permitted investments. For purposes of calculating the consolidated fixed charge coverage ratio, the calculation of consolidated EBITDA as defined in the ABL Facility is a trailing 12-month calculation that begins with the Company’s consolidated net income, with certain adjustments for interest, taxes, depreciation and amortization, net income attributable to noncontrolling interests, stock compensation expense, restructuring costs, and the financial impact of other non-cash or non-recurring items recorded during any such 12-month period. The consolidated fixed charge coverage ratio is a required covenant only in periods where the total borrowings outstanding under the ABL Facility reduce the amount available in the facility to less than the greater of (i) $95 million or (ii) 10% of the calculated borrowing base. As a result, in the event the Company has less than $95 million available under the ABL Facility, the Company would need to comply with the consolidated fixed charge coverage ratio. At June 30, 2022, the Company is not subject to the consolidated fixed charge coverage ratio as such triggering event had not occurred during the twelve months ended June 30, 2022. The Company paid interest of $168 million and $101 million on borrowings during the three months ended June 30, 2022 and 2021, respectively, and $410 million and $304 million on borrowings during the six months ended June 30, 2022 and 2021, respectively.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	7. FAIR VALUE OF FINANCIAL INSTRUMENTS The fair value of financial instruments has been estimated by the Company using available market information as of June 30, 2022 and December 31, 2021, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions): June 30, 2022 December 31, 2021 Carrying Estimated Fair Carrying Estimated Fair Amount Value Amount Value Assets: Cash and cash equivalents $ 346 $ 346 $ 507 $ 507 Investments in equity securities 115 115 144 144 Available-for-sale debt securities 177 177 178 178 Trading securities 12 12 13 13 Liabilities: 6⅝% Senior Secured Notes due 2025 — — 1,434 1,517 8% Senior Secured Notes due 2026 2,080 1,915 2,078 2,210 8% Senior Secured Notes due 2027 693 637 692 758 5⅝% Senior Secured Notes due 2027 1,826 1,613 1,819 2,011 6⅞% Senior Notes due 2028 759 455 759 758 6% Senior Secured Notes due 2029 862 744 860 966 5¼% Senior Secured Notes due 2030 1,443 1,178 — — 4¾% Senior Secured Notes due 2031 1,090 806 1,090 1,108 6⅞% Junior-Priority Secured Notes due 2029 1,633 1,158 1,625 1,823 6⅛% Junior-Priority Secured Notes due 2030 1,356 903 1,352 1,431 ABL Facility and other debt 43 43 32 32 The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the GAAP fair value hierarchy as discussed in Note 8. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets. Available-for-sale debt securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. Trading securities. Estimated fair value is based on closing price as quoted in public markets. Senior Notes, Senior Secured Notes and Junior-Priority Secured Notes. Estimated fair value is based on the closing market price for these notes. ABL Facility and other debt. The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE	8. FAIR VALUE Fair Value Hierarchy Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). The inputs used to measure fair value are classified into the following fair value hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during the six-month periods ended June 30, 2022 or 2021. The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 (in millions): June 30, 2022 Level 1 Level 2 Level 3 Investments in equity securities $ 115 $ 115 $ — $ — Available-for-sale debt securities 177 — 177 — Trading securities 12 — 12 — Total assets $ 304 $ 115 $ 189 $ — December 31, 2021 Level 1 Level 2 Level 3 Investments in equity securities $ 144 $ 144 $ — $ — Available-for-sale debt securities 178 — 178 — Trading securities 13 — 13 — Total assets $ 335 $ 144 $ 191 $ — Investments in Equity Securities, Available-for-Sale Debt Securities and Trading Securities Investments in equity securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale debt securities and trading securities primarily consisted of bonds and notes issued by the United States government and its agencies and domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
LEASES	9. LEASES The Company utilizes operating and finance leases for the use of certain hospitals, medical office buildings, and medical equipment. The components of lease cost and rent expense for the three and six months ended June 30, 2022 and 2021 are as follows (in millions): Three Months Ended June 30, Six Months Ended June 30, Lease Cost 2022 2021 2022 2021 Operating lease cost: Operating lease cost $ 53 $ 50 $ 104 $ 99 Short-term rent expense 21 23 44 47 Variable lease cost 5 6 9 12 Sublease income (1 ) (1 ) (2 ) (2 ) Total operating lease cost $ 78 $ 78 $ 155 $ 156 Finance lease cost: Amortization of right-of-use assets $ 4 $ 1 $ 7 $ 4 Interest on finance lease liabilities 4 2 8 3 Total finance lease cost $ 8 $ 3 $ 15 $ 7 Supplemental balance sheet information related to leases is as follows (in millions): Balance Sheet Classification June 30, 2022 December 31, 2021 Operating Leases: Operating lease right-of-use assets Other assets, net $ 709 $ 668 Finance Leases: Finance lease right-of-use assets Property and equipment Land and improvements $ 8 $ 8 Buildings and improvements 326 289 Equipment and fixtures 12 17 Property and equipment 346 314 Less accumulated depreciation and amortization (60 ) (54 ) Property and equipment, net $ 286 $ 260 Current finance lease liabilities Current maturities of long-term debt $ 3 $ 8 Long-term finance lease liabilities Long-term debt 268 233 Supplemental cash flow information related to leases for the six months ended June 30, 2022 and 2021 is as follows (in millions): Six Months Ended June 30, Cash flow information 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases (1) $ 101 $ 102 Operating cash flows from finance leases 8 3 Financing cash flows from finance leases 8 3 Right-of-use assets obtained in exchange for new finance lease liabilities 42 15 Right-of-use assets obtained in exchange for new operating lease liabilities 92 36 _______________________________ (1)

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
STOCKHOLDERS' DEFICIT	10. STOCKHOLDERS’ DEFICIT Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of June 30, 2022, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock. The Company is a holding company which operates through its subsidiaries. The ABL Facility and the indentures governing each series of the Company’s outstanding notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below. The ABL Facility and the indentures governing each series of the Company’s outstanding notes restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of June 30, 2022, under the most restrictive test in these agreements (and subject to certain exceptions), the Company has approximately $300 million of capacity to pay permitted dividends and/or repurchase shares of stock or make other restricted payments. The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company’s stockholders, and equity attributable to noncontrolling interests as of June 30, 2022, and during each of the three-month periods following December 31, 2021 (in millions): Community Health Systems, Inc. Stockholders Redeemable Noncontrolling Interest Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss (Income) (1) Accumulated Deficit Noncontrolling Interest Total Stockholders’ Deficit (1) Balance, December 31, 2021 $ 480 $ 1 $ 2,118 $ (14 ) $ (3,477 ) $ 82 $ (1,290 ) Comprehensive income (loss) 16 — — (8 ) (1 ) 15 6 Distributions to noncontrolling interests (12 ) — — — — (17 ) (17 ) Purchases of subsidiary shares from noncontrolling interests 1 — (1 ) — — — (1 ) Contributions from noncontrolling interests 1 — — — — — — Adjustment to redemption value of redeemable noncontrolling interests 7 — (7 ) — — — (7 ) Cancellation of restricted stock for tax withholdings on vested shares — — (8 ) — — — (8 ) Share-based compensation — — 5 — — — 5 Balance, March 31, 2022 493 1 2,107 (22 ) (3,478 ) 80 (1,312 ) Comprehensive income (loss) 21 — — (6 ) (326 ) 7 (324 ) Distributions to noncontrolling interests (39 ) — — — — (5 ) (5 ) Noncontrolling interest in acquired entity 3 — — — — 2 2 Adjustment to redemption value of redeemable noncontrolling interests 20 — (20 ) — — — (20 ) Share-based compensation — — 3 — — — 3 Balance, June 30, 2022 $ 498 $ 1 $ 2,090 $ (27 ) $ (3,804 ) $ 84 $ (1,656 ) ___________________________________ (1) Totals may not add due to rounding. The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company ’s stockholders , and equity attributable to the noncontrollin g interests as of June 30 , 2021 , and during each of the three-month period s followi ng December 31, 2020 (in millions): Community Health Systems, Inc. Stockholders Redeemable Noncontrolling Interest Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Accumulated Deficit Noncontrolling Interest Total Stockholders’ Deficit Balance, December 31, 2020 $ 484 $ 1 $ 2,094 $ (13 ) $ (3,707 ) $ 87 $ (1,538 ) Comprehensive income (loss) 21 — — (3 ) (64 ) 8 (59 ) Distributions to noncontrolling interests (12 ) — — — — (9 ) (9 ) Dispositions of less-than-wholly owned business (7 ) — — — — — — Noncontrolling interest in acquired entity 2 — — — — — — Adjustment to redemption value of redeemable noncontrolling interests (7 ) — 7 — — — 7 Cancellation of restricted stock for tax withholdings on vested shares — — (4 ) — — — (4 ) Share-based compensation — — 8 — — — 8 Balance, March 31, 2021 481 1 2,105 (16 ) (3,771 ) 86 (1,595 ) Comprehensive income 24 — — 1 6 7 14 Distributions to noncontrolling interests (31 ) — — — — (14 ) (14 ) Purchase of subsidiary shares from noncontrolling interests (2 ) — — — — — — Other reclassifications of noncontrolling interests 1 — (1 ) — — — (1 ) Adjustment to redemption value of redeemable noncontrolling interests 25 — (25 ) — — — (25 ) Share-based compensation — — 5 — — — 5 Balance, June 30, 2021 $ 498 $ 1 $ 2,084 $ (15 ) $ (3,765 ) $ 79 $ (1,616 ) The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ deficit (in millions): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Net (loss) income attributable to Community Health Systems, Inc. stockholders $ (326 ) $ 6 $ (327 ) $ (58 ) Transfers to the noncontrolling interests: Net (decrease) increase in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests — — (1 ) — Net transfers to the noncontrolling interests — — (1 ) — Change to Community Health Systems, Inc. stockholders' deficit from net (loss) income attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests $ (326 ) $ 6 $ (328 ) $ (58 )

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	11. EARNINGS PER SHARE The following table sets forth the components of the denominator for the computation of basic and diluted earnings per share for net (loss) income attributable to Community Health Systems, Inc. stockholders: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Weighted-average number of shares outstanding — basic 129,095,571 127,069,252 128,460,419 126,414,901 Effect of dilutive securities: Restricted stock awards — 2,530,006 — — Employee stock options — 800,599 — — Other equity-based awards — 337,267 — — Weighted-average number of shares outstanding — diluted 129,095,571 130,737,124 128,460,419 126,414,901 The Company generated a loss attributable to Community Health Systems, Inc. stockholders for the three months ended June 30, 2022 and both of the six-month periods ended June 30, 2022 and 2021, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income during the three months ended June 30, 2022, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase of 1,152,737 shares. If the Company had generated income during the six months ended June 30, 2022 and 2021, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase of 1,675,586 shares and 2,967,814 shares, respectively. Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive: Employee stock options and restricted stock awards 4,439,146 747,668 2,858,073 803,127

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. CONTINGENCIES The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters will have a material adverse effect on the condensed consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters. Probable Contingencies The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the six months ended June 30, 2022, with respect to the Company’s determination of the contingencies of the Company in respect of which an accrual has been recorded. The liability as of June 30, 2022 is comprised of individually insignificant amounts for various matters. Summary of Recorded Amounts Probable Contingencies Balance as of December 31, 2021 $ 20 Expense 4 Cash payments (9 ) Balance as of June 30, 2022 $ 15 In accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the condensed consolidated balance sheet and are included in the table above. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount reflected as a liability on the condensed consolidated balance sheet.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	13. SUBSEQUENT EVENTS The Company has evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the condensed consolidated financial statements. On July 1, 2022, one or more affiliates of the Company sold substantially all of the assets of AllianceHealth Seminole (32 licensed beds) in Seminole, Oklahoma, to affiliates of SSM Health Care of Oklahoma.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Accounting	The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of June 30, 2022 and December 31, 2021 and for the three-month and six-month periods ended June 30, 2022 and 2021, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2022. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions. Certain information and disclosures normally included in the notes to the consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2021, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 17, 2022 (“2021 Form 10-K”).
Reclassifications	Reclassifications . Certain prior period amounts have been reclassified to conform to the current period presentation within the condensed consolidated statements of cash flows.
Consolidation	Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets. Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company include the Company’s corporate office costs at its Franklin, Tennessee office, which were $57 million and $52 million for the three months ended June 30, 2022 and 2021, respectively, and $120 million and $112 million for the six months ended June 30, 2022 and 2021, respectively. Throughout these notes to the unaudited condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of Community Health Systems, Inc.
Revenue Recognition	Revenue Recognition. Net Operating Revenues Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions. During each of the three and six-month periods ended June 30, 2022 and 2021, the impact of changes to the inputs used to determine the transaction price was considered immaterial. Currently, several states utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (“CMS”) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and payment is reasonably assured. Reimbursement under these programs is reflected in net operating revenues. Taxes or other program-related costs are reflected in other operating expenses. The Company’s net operating revenues during the three and six months ended June 30, 2022 and 2021 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Medicare $ 616 $ 642 $ 1,285 $ 1,335 Medicaid 445 420 912 811 Managed Care and other third-party payors 1,862 1,919 3,794 3,835 Self-pay 11 26 53 39 Total $ 2,934 $ 3,007 $ 6,044 $ 6,020
Patient Accounts Receivable	Patient Accounts Receivable Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends. Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, the impact of recent acquisitions and dispositions and the impact of current economic and other events. Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $107 million and $118 million as of June 30, 2022 and December 31, 2021, respectively, and these amounts are included in accrued liabilities-other in the accompanying condensed consolidated balance sheets. Amounts due from third-party payors were $100 million and $114 million as of June 30, 2022 and December 31, 2021, respectively, and are included in other current assets in the accompanying condensed consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2017.
Charity Care	Charity Care In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government. The Company updated its policy during the three months ended March 31, 2022 in a manner which increased the number of accounts qualifying for charity care. This resulted in an increase in charity care services during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021. These charity care services are estimated to be $ 409
Accounting for the Impairment or Disposal of Long-Lived Assets	Accounting for the Impairment or Disposal of Long-Lived Assets. During the six months ended June 30, 2022, the Company recorded an impairment charge of approximately $6 million to adjust the carrying value of long-lived assets at a hospital that was subsequently sold at a sales price below carrying value. During the six months ended June 30, 2021, the Company recorded a total combined net loss on disposal of approximately $23 million, of which (i) The Company will continue to evaluate the potential for impairment of the long-lived assets of hospitals and other held-and-used businesses as well as evaluate offers for potential sales, as applicable. Based on such analysis, additional impairment charges may be recorded in the future.
Pandemic Relief Funds	Pandemic Relief Funds During the six months ended June 30, 2022 and 2021, the Company received approximately $52 million and $7 million, respectively, in pandemic relief fund payments through various federal, state and local programs. Approximately $8 million and $1 million during the three months ended June 30, 2022 and 2021, respectively, and $55 million and $83 million during the six months ended June 30, 2022 and 2021, respectively, was recognized as a reduction to operating costs and expenses, as denoted by the caption “pandemic relief funds” within the condensed consolidated statements of (loss) income. Approximately $11 million of unrecognized pandemic relief funds received are reflected within accrued liabilities-other in the condensed consolidated balance sheet as of June 30, 2022. Such unrecognized amounts may either be returned or may be recognized in future periods if the underlying conditions for recognition are reasonably assured of having been met. The Company’s accounting policies for the recognition of pandemic relief funds is unchanged from the policies described in Note 1 to the Company’s consolidated financial statements included in the 2021 Form 10-K.
Acquisitions	Acquisitions The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control of the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.
Fair Value of Financial Instruments	The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the GAAP fair value hierarchy as discussed in Note 8. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets. Available-for-sale debt securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. Trading securities. Estimated fair value is based on closing price as quoted in public markets. Senior Notes, Senior Secured Notes and Junior-Priority Secured Notes. Estimated fair value is based on the closing market price for these notes. ABL Facility and other debt. The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Net Operating Revenues	The Company’s net operating revenues during the three and six months ended June 30, 2022 and 2021 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Medicare $ 616 $ 642 $ 1,285 $ 1,335 Medicaid 445 420 912 811 Managed Care and other third-party payors 1,862 1,919 3,794 3,835 Self-pay 11 26 53 39 Total $ 2,934 $ 3,007 $ 6,044 $ 6,020

Accounting for Stock-Based Co_2

Accounting for Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation Expense	The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Effect on (loss) income before income taxes $ (3 ) $ (5 ) $ (8 ) $ (13 ) Effect on net (loss) income $ (2 ) $ (4 ) $ (7 ) $ (10 )
Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions	The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Expected volatility N/A N/A 84.3% - 87.5% 84.3% - 88.9% Expected dividends N/A N/A — — Expected term N/A N/A 3 - 6 years 3 - 6 years Risk-free interest rate N/A N/A 1.5% - 1.6% 0.3% - 0.9%
Schedule of Share-based Compensation, Stock Options, Activity	Options outstanding and exercisable under the 2009 Plan as of June 30, 2022, and changes during each of the three-month periods following December 31, 2021, was as follows (in millions, except share and per share data): Weighted- Aggregate Weighted- Average Intrinsic Average Remaining Value as of Exercise Contractual June 30, Shares Price Term 2022 Outstanding at December 31, 2021 2,301,753 $ 6.77 Granted 760,000 10.18 Exercised (56,500 ) 4.97 Forfeited and cancelled (151,002 ) 14.67 Outstanding at March 31, 2022 2,854,251 7.30 Granted — — Exercised — — Forfeited and cancelled — — Outstanding at June 30, 2022 2,854,251 $ 7.30 8.3 years $ — Exercisable at June 30, 2022 1,320,912 $ 5.63 7.5 years $ —
Schedule of Share-based Compensation, Restricted Stock, Activity	Restricted stock outstanding under the 2009 Plan as of June 30, 2022, and changes during each of the three-month periods following December 31, 2021, was as follows: Weighted- Average Grant Shares Date Fair Value Unvested at December 31, 2021 4,995,314 $ 6.30 Granted 3,179,000 9.05 Vested (2,516,247 ) 5.62 Forfeited (30,000 ) 6.87 Unvested at March 31, 2022 5,628,067 8.61 Granted 41,000 5.00 Vested (17,000 ) 10.65 Forfeited (72,670 ) 9.77 Unvested at June 30, 2022 5,579,397 8.56
Schedule of Share-based Compensation, Restricted Stock Units, Activity	RSUs outstanding under the 2009 Plan as of June 30, 2022, and changes during each of the three-month periods following December 31, 2021, was as follows: Weighted- Average Grant Shares Date Fair Value Unvested at December 31, 2021 486,598 $ 6.17 Granted 159,138 10.18 Vested (151,058 ) 5.63 Forfeited — — Unvested at March 31, 2022 494,678 7.63 Granted 17,682 5.00 Vested — — Forfeited — — Unvested at June 30, 2022 512,360 7.54

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	6 Months Ended
	Jun. 30, 2022
Acquisitions And Divestitures [Abstract]
Schedule of Divestitures	No hospitals were divested during the six months ended June 30, 2022. The following table provides a summary of hospitals that the Company divested during the year ended December 31, 2021: Licensed Hospital Buyer City, State Beds Effective Date Lea Regional Medical Center Covenant Health System Hobbs, NM 84 January 1, 2021 Tennova Healthcare - Tullahoma Vanderbilt University Medical Center Tullahoma, TN 135 January 1, 2021 Tennova Healthcare - Shelbyville Vanderbilt University Medical Center Shelbyville, TN 60 January 1, 2021 Northwest Mississippi Medical Center Delta Health System Clarksdale, MS 181 February 1, 2021 AllianceHealth Midwest SSM Health Care of Oklahoma Midwest City, OK 255 April 1, 2021

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill for the six months ended June 30, 2022 are as follows (in millions): Balance, as of December 31, 2021 Goodwill $ 7,033 Accumulated impairment losses (2,814 ) 4,219 Goodwill acquired as part of acquisitions during current year 5 Goodwill allocated to hospitals held for sale — Balance, as of June 30, 2022 Goodwill 7,038 Accumulated impairment losses (2,814 ) $ 4,224

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Instrument [Line Items]
Schedule of Debt	Long-term debt, net of unamortized deferred debt issuance costs, consists of the following (in millions): June 30, December 31, 2022 2021 6⅝ $ — $ 1,462 8% Senior Secured Notes due 2026 2,101 2,101 8% Senior Secured Notes due 2027 700 700 5⅝ 1,900 1,900 6⅞ 767 767 6% Senior Secured Notes due 2029 900 900 5¼ 1,535 — 4¾ 1,095 1,095 6⅞ 1,775 1,775 6⅛ 1,440 1,440 ABL Facility — — Finance lease and financing obligations 428 398 Other 48 37 Less: Unamortized deferred debt issuance costs and note premium (474 ) (435 ) Total debt 12,215 12,140 Less: Current maturities (32 ) (31 ) Total long-term debt $ 12,183 $ 12,109
Senior Secured Notes 5.250%, Due 2030 | Senior Secured Notes
Debt Instrument [Line Items]
Schedule of Early Redemption Prices on Notes	At any time and from time to time on or after May 15, 2025, CHS may redeem the 5¼ Period Redemption Price May 15, 2025 to May 14, 2026 102.625% May 15, 2026 to May 14, 2027 101.313% May 15, 2027 to May 14, 2030 100.000%

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping	The fair value of financial instruments has been estimated by the Company using available market information as of June 30, 2022 and December 31, 2021, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions): June 30, 2022 December 31, 2021 Carrying Estimated Fair Carrying Estimated Fair Amount Value Amount Value Assets: Cash and cash equivalents $ 346 $ 346 $ 507 $ 507 Investments in equity securities 115 115 144 144 Available-for-sale debt securities 177 177 178 178 Trading securities 12 12 13 13 Liabilities: 6⅝% Senior Secured Notes due 2025 — — 1,434 1,517 8% Senior Secured Notes due 2026 2,080 1,915 2,078 2,210 8% Senior Secured Notes due 2027 693 637 692 758 5⅝% Senior Secured Notes due 2027 1,826 1,613 1,819 2,011 6⅞% Senior Notes due 2028 759 455 759 758 6% Senior Secured Notes due 2029 862 744 860 966 5¼% Senior Secured Notes due 2030 1,443 1,178 — — 4¾% Senior Secured Notes due 2031 1,090 806 1,090 1,108 6⅞% Junior-Priority Secured Notes due 2029 1,633 1,158 1,625 1,823 6⅛% Junior-Priority Secured Notes due 2030 1,356 903 1,352 1,431 ABL Facility and other debt 43 43 32 32

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 (in millions): June 30, 2022 Level 1 Level 2 Level 3 Investments in equity securities $ 115 $ 115 $ — $ — Available-for-sale debt securities 177 — 177 — Trading securities 12 — 12 — Total assets $ 304 $ 115 $ 189 $ — December 31, 2021 Level 1 Level 2 Level 3 Investments in equity securities $ 144 $ 144 $ — $ — Available-for-sale debt securities 178 — 178 — Trading securities 13 — 13 — Total assets $ 335 $ 144 $ 191 $ —

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Components of Lease Cost and Rent Expense	The components of lease cost and rent expense for the three and six months ended June 30, 2022 and 2021 are as follows (in millions): Three Months Ended June 30, Six Months Ended June 30, Lease Cost 2022 2021 2022 2021 Operating lease cost: Operating lease cost $ 53 $ 50 $ 104 $ 99 Short-term rent expense 21 23 44 47 Variable lease cost 5 6 9 12 Sublease income (1 ) (1 ) (2 ) (2 ) Total operating lease cost $ 78 $ 78 $ 155 $ 156 Finance lease cost: Amortization of right-of-use assets $ 4 $ 1 $ 7 $ 4 Interest on finance lease liabilities 4 2 8 3 Total finance lease cost $ 8 $ 3 $ 15 $ 7
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows (in millions): Balance Sheet Classification June 30, 2022 December 31, 2021 Operating Leases: Operating lease right-of-use assets Other assets, net $ 709 $ 668 Finance Leases: Finance lease right-of-use assets Property and equipment Land and improvements $ 8 $ 8 Buildings and improvements 326 289 Equipment and fixtures 12 17 Property and equipment 346 314 Less accumulated depreciation and amortization (60 ) (54 ) Property and equipment, net $ 286 $ 260 Current finance lease liabilities Current maturities of long-term debt $ 3 $ 8 Long-term finance lease liabilities Long-term debt 268 233
Supplemental Cash Flow and Other Information Related to Leases	Supplemental cash flow information related to leases for the six months ended June 30, 2022 and 2021 is as follows (in millions): Six Months Ended June 30, Cash flow information 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases (1) $ 101 $ 102 Operating cash flows from finance leases 8 3 Financing cash flows from finance leases 8 3 Right-of-use assets obtained in exchange for new finance lease liabilities 42 15 Right-of-use assets obtained in exchange for new operating lease liabilities 92 36 (1)

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Stockholders' Deficit	The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company’s stockholders, and equity attributable to noncontrolling interests as of June 30, 2022, and during each of the three-month periods following December 31, 2021 (in millions): Community Health Systems, Inc. Stockholders Redeemable Noncontrolling Interest Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss (Income) (1) Accumulated Deficit Noncontrolling Interest Total Stockholders’ Deficit (1) Balance, December 31, 2021 $ 480 $ 1 $ 2,118 $ (14 ) $ (3,477 ) $ 82 $ (1,290 ) Comprehensive income (loss) 16 — — (8 ) (1 ) 15 6 Distributions to noncontrolling interests (12 ) — — — — (17 ) (17 ) Purchases of subsidiary shares from noncontrolling interests 1 — (1 ) — — — (1 ) Contributions from noncontrolling interests 1 — — — — — — Adjustment to redemption value of redeemable noncontrolling interests 7 — (7 ) — — — (7 ) Cancellation of restricted stock for tax withholdings on vested shares — — (8 ) — — — (8 ) Share-based compensation — — 5 — — — 5 Balance, March 31, 2022 493 1 2,107 (22 ) (3,478 ) 80 (1,312 ) Comprehensive income (loss) 21 — — (6 ) (326 ) 7 (324 ) Distributions to noncontrolling interests (39 ) — — — — (5 ) (5 ) Noncontrolling interest in acquired entity 3 — — — — 2 2 Adjustment to redemption value of redeemable noncontrolling interests 20 — (20 ) — — — (20 ) Share-based compensation — — 3 — — — 3 Balance, June 30, 2022 $ 498 $ 1 $ 2,090 $ (27 ) $ (3,804 ) $ 84 $ (1,656 ) ___________________________________ (1) Totals may not add due to rounding. The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company ’s stockholders , and equity attributable to the noncontrollin g interests as of June 30 , 2021 , and during each of the three-month period s followi ng December 31, 2020 (in millions): Community Health Systems, Inc. Stockholders Redeemable Noncontrolling Interest Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Accumulated Deficit Noncontrolling Interest Total Stockholders’ Deficit Balance, December 31, 2020 $ 484 $ 1 $ 2,094 $ (13 ) $ (3,707 ) $ 87 $ (1,538 ) Comprehensive income (loss) 21 — — (3 ) (64 ) 8 (59 ) Distributions to noncontrolling interests (12 ) — — — — (9 ) (9 ) Dispositions of less-than-wholly owned business (7 ) — — — — — — Noncontrolling interest in acquired entity 2 — — — — — — Adjustment to redemption value of redeemable noncontrolling interests (7 ) — 7 — — — 7 Cancellation of restricted stock for tax withholdings on vested shares — — (4 ) — — — (4 ) Share-based compensation — — 8 — — — 8 Balance, March 31, 2021 481 1 2,105 (16 ) (3,771 ) 86 (1,595 ) Comprehensive income 24 — — 1 6 7 14 Distributions to noncontrolling interests (31 ) — — — — (14 ) (14 ) Purchase of subsidiary shares from noncontrolling interests (2 ) — — — — — — Other reclassifications of noncontrolling interests 1 — (1 ) — — — (1 ) Adjustment to redemption value of redeemable noncontrolling interests 25 — (25 ) — — — (25 ) Share-based compensation — — 5 — — — 5 Balance, June 30, 2021 $ 498 $ 1 $ 2,084 $ (15 ) $ (3,765 ) $ 79 $ (1,616 )
Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit	The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ deficit (in millions): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Net (loss) income attributable to Community Health Systems, Inc. stockholders $ (326 ) $ 6 $ (327 ) $ (58 ) Transfers to the noncontrolling interests: Net (decrease) increase in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests — — (1 ) — Net transfers to the noncontrolling interests — — (1 ) — Change to Community Health Systems, Inc. stockholders' deficit from net (loss) income attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests $ (326 ) $ 6 $ (328 ) $ (58 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Components of Denominator for Computation of Basic and Diluted Earnings Per Share	The following table sets forth the components of the denominator for the computation of basic and diluted earnings per share for net (loss) income attributable to Community Health Systems, Inc. stockholders: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Weighted-average number of shares outstanding — basic 129,095,571 127,069,252 128,460,419 126,414,901 Effect of dilutive securities: Restricted stock awards — 2,530,006 — — Employee stock options — 800,599 — — Other equity-based awards — 337,267 — — Weighted-average number of shares outstanding — diluted 129,095,571 130,737,124 128,460,419 126,414,901
Schedule of Antidilutive Securities	The Company generated a loss attributable to Community Health Systems, Inc. stockholders for the three months ended June 30, 2022 and both of the six-month periods ended June 30, 2022 and 2021, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income during the three months ended June 30, 2022, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase of 1,152,737 shares. If the Company had generated income during the six months ended June 30, 2022 and 2021, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase of 1,675,586 shares and 2,967,814 shares, respectively. Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive: Employee stock options and restricted stock awards 4,439,146 747,668 2,858,073 803,127

Contingencies (Tables)

Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies	The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the six months ended June 30, 2022, with respect to the Company’s determination of the contingencies of the Company in respect of which an accrual has been recorded. The liability as of June 30, 2022 is comprised of individually insignificant amounts for various matters. Summary of Recorded Amounts Probable Contingencies Balance as of December 31, 2021 $ 20 Expense 4 Cash payments (9 ) Balance as of June 30, 2022 $ 15

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cost of Revenue, Policy [Abstract]
Corporate office costs	$ 57	$ 52	$ 120	$ 112
Third Party Reimbursement [Abstract]
Amounts due to third party payors	107		107		$ 118
Amounts due from third party payors	100		100		$ 114
Net Operating Revenues, Policy [Abstract]
Charity care services charges excluded from net operating revenues	409	215	772	444
Value of charity care services at the Company's standard charges included in contractual allowances	47	26	88	52
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business				(23)
Impairment charge of long-lived assets sold			6
CARES Act | Public Health And Social Services Emergency Fund | Paycheck Protection Program and Health Care Enhancement Act
CARES Act and PPPHCE Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs			52	7
CARES Act | Public Health And Social Services Emergency Fund | Accrued Liabilities - Other | Paycheck Protection Program and Health Care Enhancement Act
CARES Act and PPPHCE Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs			11
CARES Act | Operating Costs and Expenses | Public Health And Social Services Emergency Fund | Paycheck Protection Program and Health Care Enhancement Act
CARES Act and PPPHCE Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs	$ 8	$ 1	$ 55	83
Adjustment for Carrying Value of Other Long-Lived Assets at Underperforming Hospitals
Accounting for the Impairment or Disposal of Long-Lived Assets
Impairment of long-lived assets held for sale				28
Hospitals Sold or Deemed Held for Sale | Certain Hospitals
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business				(3)
Hospitals Closed
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business				(8)
Shared Service Center
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business				$ (7)

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Schedule of Net Operating Revenues (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	$ 2,934	$ 3,007	$ 6,044	$ 6,020
Medicare
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	616	642	1,285	1,335
Medicaid
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	445	420	912	811
Managed Care and Other Third Party Payors
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	1,862	1,919	3,794	3,835
Self-Pay
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	$ 11	$ 26	$ 53	$ 39

Accounting for Stock-Based Co_3

Accounting for Stock-Based Compensation - Additional Information (Details)				3 Months Ended			6 Months Ended
	Jun. 01, 2022 USD ($) shares	Mar. 01, 2022 USD ($) Director shares	Mar. 01, 2021 USD ($) Director shares	Jun. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Item $ / shares shares	Jun. 30, 2021 USD ($) Item $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, unrecognized compensation costs on nonvested awards				$ 45,000,000			$ 45,000,000
Employee service share-based compensation total compensation cost not yet recognized, period for recognition							27 months
Employee service share-based compensation, nonvested awards, modifications to awards | Item							0	0
Aggregate intrinsic value of options exercised				0		$ 0
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options exercised							$ 1,000,000	$ 1,000,000
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition							26 months
Employee service share-based compensation, unrecognized compensation costs on nonvested stock options				$ 7,000,000			$ 7,000,000
Weighted-average grant date fair value of stock options | $ / shares							$ 7.25	$ 6.22
Share Price | $ / shares				$ 3.75			$ 3.75
Restricted Stock and Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition							27 months
Employee service share-based compensation, unrecognized compensation costs on nonvested awards other than options				$ 38,000,000			$ 38,000,000
Restricted Stock, Performance-Based Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by payment award, performance objective measurement period							3 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, number of grants | shares				17,682	159,138
Number of directors elected to defer the receipt of RSUs granted | Director		3	4
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights							one-third increments on each of the first three anniversaries of the award date
Share-based compensation, number of grants | shares				41,000	3,179,000
Plan 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unissued common stock reserved for grants | shares				6,906,176			6,906,176
Share-based compensation arrangement award vesting rights							one-third increments on each of the first three anniversaries of the award date
Contractual term of option granted							10 years
Plan 2009 | Restricted Stock Units (RSUs) | Non-management Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, number of grants | shares	17,682	17,682	19,296
Fair value of units granted	$ 88,000	$ 180,000	$ 170,000
Performance-Based Awards Granted On March 1, 2018 | Restricted Stock, Performance-Based Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights, percentage		200%

Accounting for Stock-Based Co_4

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Effect on (loss) income before income taxes	$ (3)	$ (5)	$ (8)	$ (13)
Effect on net (loss) income	$ (2)	$ (4)	$ (7)	$ (10)

Accounting for Stock-Based Co_5

Accounting for Stock-Based Compensation - Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions (Details) - Employee Stock Option	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	84.30%	84.30%
Expected volatility, maximum	87.50%	88.90%
Risk-free interest rate, minimum	1.50%	0.30%
Risk-free interest rate, maximum	1.60%	0.90%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	3 years	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years	6 years

Accounting for Stock-Based Co_6

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	2,854,251	2,301,753
Granted, Shares		760,000
Exercised, Shares		(56,500)
Forfeited and cancelled, Shares		(151,002)
Ending Balance, Shares	2,854,251	2,854,251
Exercisable, Shares	1,320,912
Beginning of Period, Weighted Average Exercise Price	$ 7.30	$ 6.77
Granted, Weighted Average Exercise Price		10.18
Exercised, Weighted Average Exercise Price		4.97
Forfeited and Cancelled, Weighted Average Exercise Price		14.67
End of Period, Weighted Average Exercise Price	7.30	$ 7.30
Exercisable, Weighted Average Exercise Price	$ 5.63
Weighted Average Remaining Contractual Term	8 years 3 months 18 days
Exercisable, Weighted Average Remaining Contractual Term	7 years 6 months

Accounting for Stock-Based Co_7

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock, Activity (Details) - Restricted Stock - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	5,628,067	4,995,314
Granted, Shares	41,000	3,179,000
Vested, Shares	(17,000)	(2,516,247)
Forfeited, Shares	(72,670)	(30,000)
Ending Balance, Unvested Shares	5,579,397	5,628,067
Beginning of Period, Weighted Average Grant Date Fair Value	$ 8.61	$ 6.30
Granted, Weighted Average Grant Date Fair Value	5	9.05
Vested, Weighted Average Grant Date Fair Value	10.65	5.62
Forfeited, Weighted Average Grant Date Fair Value	9.77	6.87
End of Period, Weighted Average Grant Date Fair Value	$ 8.56	$ 8.61

Accounting for Stock-Based Co_8

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock Units, Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	494,678	486,598
Granted, Shares	17,682	159,138
Vested, Shares		(151,058)
Ending Balance, Unvested Shares	512,360	494,678
Beginning of Period, Weighted Average Grant Date Fair Value	$ 7.63	$ 6.17
Granted, Weighted Average Grant Date Fair Value	5	10.18
Vested, Weighted Average Grant Date Fair Value		5.63
End of Period, Weighted Average Grant Date Fair Value	$ 7.54	$ 7.63

Acquisitions and Divestitures -

Acquisitions and Divestitures - Acquisitions - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Physician Practices Clinics and Other Ancillary Businesses
Acquisitions and Divestitures [Line Items]
Business acquisition, cost of acquired entity, purchase price	$ 4

Acquisitions and Divestitures_2

Acquisitions and Divestitures - Divestitures - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022 Item Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of hospitals divested | Hospital	0
AllianceHealth Seminole | Seminole, Oklahoma
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds | Item	32

Acquisitions and Divestitures_3

Acquisitions and Divestitures - Schedule of Divestitures (Details)	12 Months Ended
	Dec. 31, 2021 Item
Lea Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	84
Effective Date	Jan. 01, 2021
Tennova Healthcare - Tullahoma
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	135
Effective Date	Jan. 01, 2021
Tennova Healthcare - Shelbyville
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	60
Effective Date	Jan. 01, 2021
Northwest Mississippi Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	181
Effective Date	Feb. 01, 2021
Alliance Health Midwest
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	255
Effective Date	Apr. 01, 2021

Goodwill - Schedule of Goodwill

Goodwill - Schedule of Goodwill (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Goodwill Roll Forward
Goodwill	$ 7,038	$ 7,033
Accumulated impairment losses	(2,814)	(2,814)
Goodwill	4,224	$ 4,219
Goodwill acquired as part of acquisitions during current year	$ 5

Goodwill - Additional Informati

Goodwill - Additional Information (Details)	3 Months Ended
	Dec. 31, 2021 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Impairment of goodwill	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Taxes [Line Items]
Provision for income taxes	$ 200,000,000	$ 54,000,000	$ 223,000,000	$ 123,000,000
Effective income tax rate	(204.10%)	59.30%	(495.60%)	98.40%
Income tax refunds (payments), net	$ (4,000,000)	$ (1,000,000)	$ (6,000,000)	$ (1,000,000)
Federal | Tax Year 2018
Income Taxes [Line Items]
Open tax year			2018
Maximum
Income Taxes [Line Items]
Unrecognized benefit that would affect the effective tax rate	1,000,000		$ 1,000,000
Amount of interest and penalties included in liabilities for uncertain tax positions	$ 1,000,000		$ 1,000,000

Long-Term Debt - Schedule of De

Long-Term Debt - Schedule of Debt (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt and lease obligations	$ 12,215	$ 12,140
Less: Unamortized deferred debt issuance costs and note premium	(474)	(435)
Less: Current maturities	(32)	(31)
Total long-term debt	12,183	12,109
Senior Secured Notes | Senior Secured Notes at 6.625%, Due 2025
Debt Instrument [Line Items]
Debt and lease obligations		1,462
Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt and lease obligations	2,101	2,101
Senior Secured Notes | Senior Secured Notes at 8%, Due 2027
Debt Instrument [Line Items]
Debt and lease obligations	700	700
Senior Secured Notes | Senior Secured Notes at 5.625% due 2027
Debt Instrument [Line Items]
Debt and lease obligations	1,900	1,900
Senior Secured Notes | Senior Secured Notes at 6%, Due 2029
Debt Instrument [Line Items]
Debt and lease obligations	900	900
Senior Secured Notes | Senior Secured Notes 5.250%, Due 2030
Debt Instrument [Line Items]
Debt and lease obligations	1,535
Senior Secured Notes | Senior Secured Notes at 4.75%, Due 2031
Debt Instrument [Line Items]
Debt and lease obligations	1,095	1,095
Senior Notes | Senior Notes at 6.875%, Due 2028
Debt Instrument [Line Items]
Debt and lease obligations	767	767
Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.875%, Due 2029
Debt Instrument [Line Items]
Debt and lease obligations	1,775	1,775
Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.125%, Due 2030
Debt Instrument [Line Items]
Debt and lease obligations	1,440	1,440
Finance Lease and Financing Obligations
Debt Instrument [Line Items]
Debt and lease obligations	428	398
Other
Debt Instrument [Line Items]
Debt and lease obligations	$ 48	$ 37

Long-Term Debt - Schedule of _2

Long-Term Debt - Schedule of Debt (Parenthetical) (Details)		6 Months Ended	12 Months Ended
	Feb. 04, 2022	Jun. 30, 2022	Dec. 31, 2021
Senior Secured Notes | Senior Secured Notes at 6.625%, Due 2025
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	6.625%	6.625%	6.625%
Debt instrument, maturity year	2025	2025	2025
Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		8%	8%
Debt instrument, maturity year		2026	2026
Senior Secured Notes | Senior Secured Notes at 8%, Due 2027
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		8%	8%
Debt instrument, maturity year		2027	2027
Senior Secured Notes | Senior Secured Notes at 5.625% due 2027
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.625%	5.625%
Debt instrument, maturity year		2027	2027
Senior Secured Notes | Senior Secured Notes 5.250%, Due 2030
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	5.25%	5.25%	5.25%
Debt instrument, maturity year	2030	2030	2030
Senior Secured Notes | Senior Secured Notes at 4.75%, Due 2031
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.75%	4.75%
Debt instrument, maturity year		2031	2031
Senior Secured Notes | Senior Secured Notes at 6%, Due 2029
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		6%	6%
Debt instrument, maturity year		2029	2029
Senior Notes | Senior Notes at 6.875%, Due 2028
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		6.875%	6.875%
Debt instrument, maturity year		2028	2028
Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.875%, Due 2029
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		6.875%	6.875%
Debt instrument, maturity year		2029	2029
Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.125%, Due 2030
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		6.125%	6.125%
Debt instrument, maturity year		2030	2030

Long-Term Debt - 5.250% Senior

Long-Term Debt - 5.250% Senior Secured Notes, Due 2030 - Additional Information (Details) - Senior Secured Notes - USD ($) $ in Millions		6 Months Ended	12 Months Ended
	Feb. 04, 2022	Jun. 30, 2022	Dec. 31, 2021
Senior Secured Notes 5.250%, Due 2030
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 04, 2022
Debt instrument aggregate principal amount	$ 1,535
Debt instrument stated interest rate	5.25%	5.25%	5.25%
Debt instrument, maturity date	May 15, 2030
Debt instrument, maturity year	2030	2030	2030
Debt instrument optional redemption date	May 15, 2025
Minimum period notice for redemption of debt	10 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption price percentage	100%
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 5¼% Senior Secured Notes due 2030.
Minimum period notice for redemption of debt	10 days
Maximum period notice for redemption of debt	60 days
Senior Secured Notes 5.250%, Due 2030 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument stated interest rate	5.25%
Debt instrument, maturity year	2030
Debt instrument optional redemption date	May 15, 2025
Debt instrument redemption price percentage	105.25%
Debt instrument redemption description		plus accrued and unpaid interest, if any. In addition, any time prior to May 15, 2025, but not more than once during each twelve-month period
Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed	40%
Senior Secured Notes 5.250%, Due 2030 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	103%
Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed	10%
Senior Secured Notes at 6.625%, Due 2025
Debt Instrument [Line Items]
Debt instrument stated interest rate	6.625%	6.625%	6.625%
Debt instrument, maturity year	2025	2025	2025
Debt instrument redemption date	Feb. 04, 2022

Long-Term Debt - Schedule of Ea

Long-Term Debt - Schedule of Early Redemption Prices on 5.250% Senior Notes, Due 2030 (Details) - Senior Secured Notes - Senior Secured Notes 5.250%, Due 2030	Feb. 04, 2022
Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage	102.625%
Debt Instrument, Redemption Period, Start Date	May 15, 2025
Debt Instrument, Redemption Period, End Date	May 14, 2026
Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	101.313%
Debt Instrument, Redemption Period, Start Date	May 15, 2026
Debt Instrument, Redemption Period, End Date	May 14, 2027
Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Debt instrument redemption price percentage	100%
Debt Instrument, Redemption Period, Start Date	May 15, 2027
Debt Instrument, Redemption Period, End Date	May 14, 2030

Long-Term Debt - Other Debt - A

Long-Term Debt - Other Debt - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Apr. 03, 2018
Debt Instrument [Line Items]
Interest paid on borrowings	$ 168,000,000	$ 101,000,000	$ 410,000,000	$ 304,000,000
ABL Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	978,000,000		978,000,000		$ 1,000,000,000
Line of credit facility, excess availability	894,000,000		894,000,000
Line of credit outstanding amount	0		0
ABL Facility | ABL Facility Customary Covenants
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	95,000,000		$ 95,000,000
Debt instrument variable interest rate			10%
ABL Facility | Letter of Credit
Debt Instrument [Line Items]
Line of credit outstanding amount	$ 84,000,000		$ 84,000,000
Reduction in letters of credit			$ 19,000,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Carrying Amount
Assets:
Cash and cash equivalents	$ 346	$ 507
Investments in equity securities	115	144
Available-for-sale debt securities	177	178
Trading securities	12	13
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 6.625% Due 2025
Liabilities:
Notes payable, fair value disclosure		1,434
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Liabilities:
Notes payable, fair value disclosure	2,080	2,078
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 8% Due 2027
Liabilities:
Notes payable, fair value disclosure	693	692
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 5.625% due 2027
Liabilities:
Notes payable, fair value disclosure	1,826	1,819
Carrying Amount | Senior Secured Notes | Senior Notes at 6% Due 2029
Liabilities:
Notes payable, fair value disclosure	862	860
Carrying Amount | Senior Secured Notes | Senior Secured Notes 5.25%, Due 2030
Liabilities:
Notes payable, fair value disclosure	1,443
Carrying Amount | Senior Secured Notes | Senior Secured Notes at 4.750% due 2031
Liabilities:
Notes payable, fair value disclosure	1,090	1,090
Carrying Amount | Senior Notes | Senior Notes at 6.875% Due 2028
Liabilities:
Notes payable, fair value disclosure	759	759
Carrying Amount | Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.875% Due 2029
Liabilities:
Notes payable, fair value disclosure	1,633	1,625
Carrying Amount | Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.125% Due 2030
Liabilities:
Notes payable, fair value disclosure	1,356	1,352
Carrying Amount | ABL Facility and Other Debt
Liabilities:
Notes payable, fair value disclosure	43	32
Estimated Fair Value
Assets:
Cash and cash equivalents	346	507
Investments in equity securities	115	144
Available-for-sale debt securities	177	178
Trading securities	12	13
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 6.625% Due 2025
Liabilities:
Notes payable, fair value disclosure		1,517
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 8%, Due 2026
Liabilities:
Notes payable, fair value disclosure	1,915	2,210
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 8% Due 2027
Liabilities:
Notes payable, fair value disclosure	637	758
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 5.625% due 2027
Liabilities:
Notes payable, fair value disclosure	1,613	2,011
Estimated Fair Value | Senior Secured Notes | Senior Notes at 6% Due 2029
Liabilities:
Notes payable, fair value disclosure	744	966
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes 5.25%, Due 2030
Liabilities:
Notes payable, fair value disclosure	1,178
Estimated Fair Value | Senior Secured Notes | Senior Secured Notes at 4.750% due 2031
Liabilities:
Notes payable, fair value disclosure	806	1,108
Estimated Fair Value | Senior Notes | Senior Notes at 6.875% Due 2028
Liabilities:
Notes payable, fair value disclosure	455	758
Estimated Fair Value | Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.875% Due 2029
Liabilities:
Notes payable, fair value disclosure	1,158	1,823
Estimated Fair Value | Junior Priority Secured Notes | Junior-Priority Secured Notes at 6.125% Due 2030
Liabilities:
Notes payable, fair value disclosure	903	1,431
Estimated Fair Value | ABL Facility and Other Debt
Liabilities:
Notes payable, fair value disclosure	$ 43	$ 32

Fair Value - Additional Informa

Fair Value - Additional Information (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0	0
Fair value, liabilities, level 1 to level 2 transfers, amount	0	0
Fair value, liabilities, level 2 to level 1 transfers, amount	$ 0	$ 0

Fair Value - Schedule of Fair V

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments in equity securities	$ 115	$ 144
Available-for-sale debt securities	177	178
Trading securities	12	13
Total assets	304	335
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments in equity securities	115	144
Total assets	115	144
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities	177	178
Trading securities	12	13
Total assets	$ 189	$ 191

Leases - Components of Lease Co

Leases - Components of Lease Cost and Rent Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating lease cost	$ 53	$ 50	$ 104	$ 99
Short-term rent expense	21	23	44	47
Variable lease cost	5	6	9	12
Sublease income	(1)	(1)	(2)	(2)
Total operating lease cost	78	78	155	156
Finance lease cost:
Amortization of right-of-use assets	4	1	7	4
Interest on finance lease liabilities	4	2	8	3
Total finance lease cost	$ 8	$ 3	$ 15	$ 7

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Operating Leases:
Operating lease right-of-use assets	$ 709	$ 668
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets, net	Other assets, net
Finance Leases:
Property and equipment	$ 9,759	$ 9,757
Less accumulated depreciation and amortization	(4,220)	(4,204)
Property and equipment, net	5,539	5,553
Current finance lease liabilities	$ 3	$ 8
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current maturities of long-term debt	Current maturities of long-term debt
Long-term finance lease liabilities	$ 268	$ 233
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt	Long-term debt
Finance Lease right-of-use Assets
Finance Leases:
Property and equipment	$ 346	$ 314
Less accumulated depreciation and amortization	(60)	(54)
Property and equipment, net	286	260
Finance Lease right-of-use Assets | Land and Improvements
Finance Leases:
Property and equipment	8	8
Finance Lease right-of-use Assets | Building and Improvements
Finance Leases:
Property and equipment	326	289
Finance Lease right-of-use Assets | Equipment and Fixtures
Finance Leases:
Property and equipment	$ 12	$ 17

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases	$ 101	$ 102
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases	8	3
Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from finance leases	8	3
Right-of-use assets obtained in exchange for new finance lease liabilities	42	15
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 92	$ 36

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Capital stock, shares authorized	400,000,000
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value per share	$ 0.01	$ 0.01
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares outstanding	0
Amount available for dividend payments, stock repurchases at period end	$ 300

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Stockholders' Deficit (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021
Equity, beginning balance	$ (1,312)	$ (1,290)	$ (1,595)	$ (1,538)
Redeemable Noncontrolling Interests, beginning balance		480
Comprehensive income (loss)	(324)	6	14	(59)
Distributions to noncontrolling interests	(5)	(17)	(14)	(9)
Purchases of subsidiary shares from noncontrolling interests		(1)
Other reclassifications of noncontrolling interests			(1)
Noncontrolling interest in acquired entity	2
Adjustment to redemption value of redeemable noncontrolling interests	(20)	(7)	(25)	7
Cancellation of restricted stock for tax withholdings on vested shares		(8)		(4)
Share-based compensation	3	5	5	8
Equity, ending balance	(1,656)	(1,312)	(1,616)	(1,595)
Redeemable Noncontrolling Interests, ending balance	498
Redeemable Noncontrolling Interests (Non- Equity)
Redeemable Noncontrolling Interests, beginning balance	493	480	481	484
Comprehensive income (loss)	21
Comprehensive income (loss) attributable to redeemable noncontrolling interest		16	24	21
Distributions to noncontrolling interests	(39)
Distributions to redeemable noncontrolling interests		(12)	(31)	(12)
Dispositions of less-than-wholly owned business				(7)
Purchases of subsidiary shares from noncontrolling interests		1	(2)
Contributions from noncontrolling interests		1
Other reclassifications of redeemable noncontrolling interests			1
Noncontrolling interest in acquired entity	3			2
Adjustment to redemption value of redeemable noncontrolling interests	20	7	25	(7)
Redeemable Noncontrolling Interests, ending balance	498	493	498	481
Common Stock
Equity, beginning balance	1	1	1	1
Equity, ending balance	1	1	1	1
Additional Paid-in Capital
Equity, beginning balance	2,107	2,118	2,105	2,094
Purchases of subsidiary shares from noncontrolling interests		(1)
Other reclassifications of noncontrolling interests			(1)
Adjustment to redemption value of redeemable noncontrolling interests	(20)	(7)	(25)	7
Cancellation of restricted stock for tax withholdings on vested shares		(8)		(4)
Share-based compensation	3	5	5	8
Equity, ending balance	2,090	2,107	2,084	2,105
Accumulated Other Comprehensive (Income) Loss
Equity, beginning balance	(22)	(14)	(16)	(13)
Comprehensive income (loss)	(6)	(8)	1	(3)
Equity, ending balance	(27)	(22)	(15)	(16)
Accumulated Deficit
Equity, beginning balance	(3,478)	(3,477)	(3,771)	(3,707)
Comprehensive income (loss)	(326)	(1)	6	(64)
Equity, ending balance	(3,804)	(3,478)	(3,765)	(3,771)
Noncontrolling Interest
Equity, beginning balance	80	82	86	87
Comprehensive income (loss)	7	15	7	8
Distributions to noncontrolling interests	(5)	(17)	(14)	(9)
Noncontrolling interest in acquired entity	2
Equity, ending balance	$ 84	$ 80	$ 79	$ 86

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Equity [Abstract]
Net (loss) income attributable to Community Health Systems, Inc. stockholders	$ (326)	$ 6	$ (327)	$ (58)
Net (decrease) increase in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests			(1)	0
Net transfers to the noncontrolling interests			(1)
Change to Community Health Systems, Inc. stockholders' deficit from net (loss) income attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$ (326)	$ 6	$ (328)	$ (58)

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Components of Denominator for Computation of Basic and Diluted Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Effect of dilutive securities:
Weighted-average number of shares outstanding — basic	129,095,571	127,069,252	128,460,419	126,414,901
Restricted stock awards		2,530,006
Employee stock options		800,599
Other equity-based awards		337,267
Weighted-average number of shares outstanding — diluted	129,095,571	130,737,124	128,460,419	126,414,901

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Details) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Increase in number of shares to diluted shares calculation if income would have been generated	1,152,737	1,675,586	2,967,814

Earnings Per Share - Schedule_2

Earnings Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Employee stock options and restricted stock awards excluded from computation of earnings per share amount	4,439,146	747,668	2,858,073	803,127

Contingencies - Schedule of Rec

Contingencies - Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies (Details) - Pending Litigation [Member] - Other Probable Contingencies [Member] $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Loss Contingency Accrual [Roll Forward]
Beginning Balance	$ 20
Expense	4
Cash payments	(9)
Ending Balance	$ 15